Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18661495rdf:typepubmed:Citationlld:pubmed
pubmed-article:18661495lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0007559lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0746883lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0250480lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0246584lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:18661495lifeskim:mentionsumls-concept:C1880496lld:lifeskim
pubmed-article:18661495pubmed:issue6lld:pubmed
pubmed-article:18661495pubmed:dateCreated2008-10-15lld:pubmed
pubmed-article:18661495pubmed:abstractTextThe aim of this randomized study was to evaluate the efficacy of cefozopran monotherapy and piperacillin-tazobactam plus ceftazidime (PIPC/TAZ + CAZ) combination therapy in pediatric neutropenic patients.lld:pubmed
pubmed-article:18661495pubmed:languageenglld:pubmed
pubmed-article:18661495pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:citationSubsetIMlld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18661495pubmed:statusMEDLINElld:pubmed
pubmed-article:18661495pubmed:monthDeclld:pubmed
pubmed-article:18661495pubmed:issn1545-5017lld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:KobayashiKuni...lld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:KobayashiRyoj...lld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:SatoTomonobuTlld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:KanedaMakotoMlld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:IguchiAkihiro...lld:pubmed
pubmed-article:18661495pubmed:authorpubmed-author:YasudaKazueKlld:pubmed
pubmed-article:18661495pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18661495pubmed:volume51lld:pubmed
pubmed-article:18661495pubmed:ownerNLMlld:pubmed
pubmed-article:18661495pubmed:authorsCompleteYlld:pubmed
pubmed-article:18661495pubmed:pagination774-7lld:pubmed
pubmed-article:18661495pubmed:dateRevised2009-1-12lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:meshHeadingpubmed-meshheading:18661495...lld:pubmed
pubmed-article:18661495pubmed:year2008lld:pubmed
pubmed-article:18661495pubmed:articleTitleA prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.lld:pubmed
pubmed-article:18661495pubmed:affiliationDepartment of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan. t-satou@jacls.jplld:pubmed
pubmed-article:18661495pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18661495pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18661495pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18661495pubmed:publicationTypeMulticenter Studylld:pubmed